A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways

How sex and age affect immune responses, susceptibility to infections, and response to vaccination

(2015) Carmen Giefing-Kröll et al.   AGING CELL

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

(2015) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic and predictive value of PDL1 expression in breast cancer

(2015) Renaud Sabatier et al.   Oncotarget

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab

(2015) Roberto Salgado et al.   JAMA Oncology

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

(2014) S. Loi et al.   ANNALS OF ONCOLOGY

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy

(2014) Gautier Stoll et al.   OncoImmunology

Construction of novel immune-related signature for prediction of pathological complete response to neoadjuvant chemotherapy in human breast cancer

(2013) Y. Sota et al.   ANNALS OF ONCOLOGY

Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications

(2013) Mario Giuliano et al.   Breast Care

CD4+ follicular helper T cell infiltration predicts breast cancer survival

(2013) Chunyan Gu-Trantien et al.   JOURNAL OF CLINICAL INVESTIGATION

Prognostic gene signatures for patient stratification in breast cancer - accuracy, stability and interpretability of gene selection approaches using prior knowledge on protein-protein interactions

(2012) Yupeng Cun et al.   BMC BIOINFORMATICS

Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer

(2012) Q. Wang et al.   CANCER RESEARCH

Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis

(2012) Michail Ignatiadis et al.   JOURNAL OF CLINICAL ONCOLOGY

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

Gonadal steroids and humoral immunity

(2012) Sanaz Sakiani et al.   Nature Reviews Endocrinology

Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients

(2011) Patricia de Cremoux et al.   BMC CANCER

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer

(2011) Sahar M.A. Mahmoud et al.   JOURNAL OF CLINICAL ONCOLOGY

Kinome expression profiling and prognosis of basal breast cancers

(2011) Renaud Sabatier et al.   Molecular Cancer

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Homogeneous Datasets of Triple Negative Breast Cancers Enable the Identification of Novel Prognostic and Predictive Signatures

(2011) Thomas Karn et al.   PLoS One

Network Based Consensus Gene Signatures for Biomarker Discovery in Breast Cancer

(2011) Holger Fröhlich   PLoS One

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

(2011) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of Subtypes in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Reveals a Gene Signature Prognostic of Outcome

(2010) Johan Staaf et al.   JOURNAL OF CLINICAL ONCOLOGY

A pathway-based classification of human breast cancer

(2010) M. L. Gatza et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

(2008) C. Desmedt et al.   CLINICAL CANCER RESEARCH

Stromal gene expression predicts clinical outcome in breast cancer

(2008) Greg Finak et al.   NATURE MEDICINE

STRING 8--a global view on proteins and their functional interactions in 630 organisms

(2008) L. J. Jensen et al.   NUCLEIC ACIDS RESEARCH

Sexual dimorphism of humoral immunity with human vaccines

(2008) Ian Francis Cook   VACCINE